Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).

被引：32

作者：

Appleman, Leonard Joseph

Puligandla, Maneka

Pal, Sumanta K.

Harris, Wayne

Agarwal, Neeraj

Costello, Brian Addis

Ryan, Christopher W.

Pins, Michael

Kolesar, Jill

Vaena, Daniel A.

Parikh, Rahul Atul

Hashmi, Mehmood

Dutcher, Janice P.

DiPaola, Robert S.

Haas, Naomi B.

Carducci, Michael Anthony

机构：

[1] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[4] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA

[5] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[6] Mayo Clin, Rochester, MN USA

[7] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[8] Univ Illinois, Coll Med, Chicago, IL USA

[9] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[10] Univ Iowa Hosp & Clin, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA

[11] Univ Kansas, Ctr Canc, Westwood, KS USA

[12] Univ Kansas, Kansas City, KS USA

[13] Canc Res Fdn NY, Bronx, NY USA

[14] Univ Kentucky, Lexington, KY USA

[15] Penn Med Abramson Canc Ctr, Philadelphia, PA USA

[16] Johns Hopkins, Sidney Kimmel Canc Ctr, Baltimore, MD USA

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.4502

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4502

引用

页数：2